U.S. Markets open in 2 hrs 24 mins
  • S&P Futures

    4,160.75
    -15.00 (-0.36%)
     
  • Dow Futures

    34,097.00
    -109.00 (-0.32%)
     
  • Nasdaq Futures

    12,753.00
    -23.75 (-0.19%)
     
  • Russell 2000 Futures

    1,966.40
    -12.90 (-0.65%)
     
  • Crude Oil

    77.87
    +0.73 (+0.95%)
     
  • Gold

    1,893.50
    +8.70 (+0.46%)
     
  • Silver

    22.48
    +0.30 (+1.37%)
     
  • EUR/USD

    1.0746
    +0.0015 (+0.1397%)
     
  • 10-Yr Bond

    3.6740
    0.0000 (0.00%)
     
  • Vix

    18.88
    -0.55 (-2.83%)
     
  • GBP/USD

    1.2096
    +0.0044 (+0.3689%)
     
  • USD/JPY

    130.8200
    -0.2520 (-0.1923%)
     
  • BTC-USD

    23,174.79
    +168.59 (+0.73%)
     
  • CMC Crypto 200

    534.95
    +8.99 (+1.71%)
     
  • FTSE 100

    7,918.16
    +53.45 (+0.68%)
     
  • Nikkei 225

    27,606.46
    -79.01 (-0.29%)
     

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Compass Therapeutics
Compass Therapeutics

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which is taking place at the Lotte New York Palace November 29 – December 1, 2022.

Presentation details:

Date: Thursday, December 1, 2022
Time: 8:50 – 9:10 AM ET
Webcast: the link will be available on the Events section of the website

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
Mario Corso, Executive Director and Head of Investor Relations
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099